Board of Directors
DR. STEFAN LEMPERLE, Chairman
Dr. Stefan Lemperle founded AscentX Medical, Inc. in April 2008 and has since served as the Company's President and CEO. From January 2007 to April 2009, Dr. Lemperle was the President and CEO of Clinicon Corporation, a privately held medical technology company that develops, manufactures and markets fractional CO2 lasers and diamond laser scalpels. In April 1999, Dr. Lemperle co-founded Artes Medical Inc., a NASDAQ-listed medical technology company, which developed and secured FDA approval for the first and only permanent injectable wrinkle filler (ArteFill®) (acquired by Suneva Medical, Inc. in 2009). He served as Vice-Chairman of the Board of Directors and President & Chief Executive Officer of Artes Medical Inc. from April 1999 to December 2006. In 1996, Dr. Lemperle co-founded MacroPore Inc. (now Cytori Therapeutics Inc., NASDAQ: CYTX), a medical technology company focused on the design, manufacture and distribution of bio-degradable bone fixation and regeneration devices for craniofacial and spine surgery. He served as Vice-Chairman of MacroPore, Inc.'s Board of Directors, Executive Vice President R&D, and Chief Scientific Officer between 1996-2000.
Dr. Lemperle was a sponsored post-doctorate research fellow at the University of California, San Diego, Division of Plastic Surgery, from July 1994 to October 1996 (German Research Society "DFG"). In 1992, Dr. Lemperle received both his M.D. and Dr. med. degrees from the Johann Wolfgang von Goethe University Frankfurt/Main, Germany where he also trained in general surgery between 1992-1994. Between 1985-1997, Dr. Lemperle was a regular team member of INTERPLAST Germany, where he participated in yearly reconstructive surgery missions to Third World countries throughout the world.
Dr. Lemperle is author/co-author of various scientific publications in the fields of Liver Transplantation, Bone Regeneration, Aesthetic Surgery, GERD and SUI. Dr. Lemperle holds various patents in medical technology. In 2005, Dr. Lemperle was a San Diego finalist for the Ernst & Young Entrepreneur of the Year® Awards.
ARTHUR A. ALFARO, Director
Mr. Alfaro has 30 years of experience in the medical device industry with 20 years in senior management. Currently, he is President, CEO and Co-founder of Nextremity Solutions, Inc., which sells medical devices for the correction of small bone degeneration, deformity and trauma. Prior to Nextremity Solutions, Mr. Alfaro was Founder, President and CEO of ORTHOCON, a drug-delivery medical device company focused on technology for postoperative pain management. He also has held the positions of President, COO and Director, Osteotech, Inc., a publicly traded orthobiologics company and President, Sofamor Danek Thoracolumbar, a medical device company, which was the largest worldwide spine company prior to being acquired by Medtronic, Inc. for $3.5 billion.
Previously, Mr. Alfaro held the positions of President, Sulzer Carbomedics, Inc. the largest manufacturer of mechanical heart valves and VP & General Manager, Microvasive Boston Scientific Corporation that was a leader in providing medical devices for gastrointestinal endoscopic procedures. Mr. Alfaro started his medical industry career at Ethicon, Inc., a Johnson & Johnson Company and worldwide leader in wound management where he held positions in sales management, marketing and international market development.
Mr. Alfaro has a BS degree from the University of Maryland and an MBA from Fairleigh Dickinson University. He is currently on the boards of Advanced Vertebral Solutions and Sun-to-Sun, Solar Energy Company.
PROF. GLEN LEHMAN, M.D., Director
Since 1987 Professor Glen Lehman has served as a Professor of Medicine & Radiology, Division of Gastroenterology/Hepatology at the Indiana University School of Medicine, Indianapolis, Indiana. Professor Lehman served or has served as a consultant to various healthcare companies including Glaxo Smith Kline, Eli Lilly, AstraZeneca, Hoffman LaRoche, Enteric Medical, Wilson-Cook, Bioform, Endonetics, Olympus America, Boston Scientific.
From 1969 to 1972, Professor Lehman performed his residency and fellowship (Gastroenterology) at the Indiana University Medical Center. From 1968 to 1969 he performed an internship at Duke University. Professor Lehman received his M.D. from Indiana University School of Medicine in 1968.
In 1996 Professor Lehman was the recipient of the Rudolf Schindler Award presented by the American Society for Gastrointestinal Endoscopy.
PROF. GOTTFRIED LEMPERLE, M.D., PH.D, Director
Professor Gottfried Lemperle joined AscentX Medical, Inc. as a co-founder in October 2008 and currently serves as the Company's Chief Medical Officer. Dr. Lemperle was a Voluntary Clinical Professor at the University of California, San Diego School of Medicine, Department of Surgery, Division of Plastic Surgery from 1998 to 2010. In April, 1999, Professor Lemperle co-founded Artes Medical Inc., a publicly held medical technology company based on his invention of the PMMA microsphere platform technology leading to the first and only FDA approved permanent injectable wrinkle filler (ArteFill®) in 2006. He served as Chief Scientific Officer of Artes Medical Inc. from August 1999 to May 2006. Prior to Artes Medical, Professor Lemperle spent over 30 years as Professor & Head of the Division of Plastic & Reconstructive Surgery at the University of Frankfurt/Main, Germany.
Professor Lemperle was awarded M.D. and Ph.D. degrees in Immunology and General and Plastic Surgery from Frankfurt University. He has authored more than 270 original publications in the fields of Plastic Surgery, GERD and SUI.
In 1997 Prof. Lemperle received the Cross of Merit 1st Class (Bundesverdienstkreuz 1. Klasse) from the President of the Republic of Germany for his achievements as founder of INTERPLAST Germany, a non-profit organization providing reconstructive surgery services in third world countries around the world. In 2010 Prof. Lemperle received the Dieffenbach-Medal as a German Lifetime Award for his contributions to the field of Plastic & Reconstructive Surgery.